European Rare Blood Disorders Platform (ENROL)

Recruiting Observational Study
Anemia Bone Marrow Failure Bleeding Disorder Iron Metabolism Disorders Myeloma Lymphoid Neoplasm Myeloma, Malignant Leukemia Anemia, Sickle Cell Thalassemia Blood Cancer Red Cell Membrane and Enzyme Abnormalities
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
Up to 100
Sex
Any
Study type
Observational
Participants needed
37,090 (estimated)
Sponsor
Hospital Universitari Vall d'Hebron Research Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
ENROL, the European Rare Blood Disorders Platform has been conceived in the core of ERN-EuroBloodNet as an umbrella for both new and already existing registries on Rare Hematological Diseases (RHDs). ENROL aims at avoiding fragmentation of data by promoting the standards for patient registries' interoperability released by the EU RD platform. ENROL's principle is to maximize public benefit from d…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients must meet all of the following criteria to be included in the ENROL Registry * Age from 0-100, both female and male * Diagnosed as RHDs according to ORPHANET classification * Able and willing to provide written informed consent (patient or legal representative for min…
Contacts

María del Mar Manú Pereira, PhD

+34934893000

mar.manu@vhir.org

CONTACT

Victoria Gutiérrez Valle, Biotech

+34934893000

victoria.gutierrez@vhir.org

CONTACT